000285023 001__ 285023
000285023 005__ 20260205151857.0
000285023 0247_ $$2doi$$a10.1192/j.eurpsy.2026.10153
000285023 0247_ $$2pmid$$apmid:41572662
000285023 0247_ $$2ISSN$$a0924-9338
000285023 0247_ $$2ISSN$$a1778-3585
000285023 037__ $$aDZNE-2026-00148
000285023 041__ $$aEnglish
000285023 082__ $$a610
000285023 1001_ $$00000-0002-1067-1495$$aMartino-Adami, Pamela V$$b0
000285023 245__ $$aExploring blood-based biomarkers in late-life depression: Correlates of psychotherapeutic treatment outcomes.
000285023 260__ $$aCambridge$$bCambridge University Press$$c2026
000285023 3367_ $$2DRIVER$$aarticle
000285023 3367_ $$2DataCite$$aOutput Types/Journal article
000285023 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770300912_11293
000285023 3367_ $$2BibTeX$$aARTICLE
000285023 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285023 3367_ $$00$$2EndNote$$aJournal Article
000285023 520__ $$aMajor depressive disorder is a prevalent and debilitating mental health condition contributing to a growing global burden. Late-life depression (LLD), affecting individuals over 60 years of age, is further associated with elevated risks for cardiovascular diseases, cognitive decline, and dementia. Treatment responses vary widely, potentially due to underlying neurodegeneration and cellular senescence. We aimed to explore blood-based biomarkers related to Alzheimer's disease and senescence-associated secretory phenotype (SASP) proteins, seeking to identify biological underpinnings of LLD and their association with response to psychotherapy.We performed a secondary analysis of the Cognitive Behavioral Therapy for Late-Life Depression (CBTlate) trial in 228 participants aged 60 years and older with a diagnosis of LLD. Depression trajectories were compared using clustering. In participants with available plasma samples, biomarker data were generated post hoc. We assessed associations between biomarkers and depression trajectories, biomarker dynamics, and their ability to predict treatment response.Two depression trajectories were identified: persistently high stable Geriatric Depression Scale (GDS) scores (hsGDS) and decreasing scores over time (dGDS). The hsGDS group had more severe baseline depression (p = 2.88 × 10-6), anxiety (p = 4.39 × 10-4), and sleep disorders (p = 1.09 × 10-3), and was more likely to have a history of major depression (p = 0.01) and mild cognitive impairment (p = 0.01). Biomarker analysis revealed elevated baseline plasma neurofilament light chain (NfL, p = 2.51 × 10-2) and reduced C-X-C Motif Chemokine Ligand 5 (CXCL5, p = 2.83 × 10-2) in the hsGDS group. Including CXCL5 in predictive models improved trajectory differentiation (p = 3.94 × 10-3).Cellular aging biomarkers like CXCL5 may improve understanding of LLD and guide personalized therapeutic interventions.
000285023 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285023 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285023 650_7 $$2Other$$ablood-based biomarkers
000285023 650_7 $$2Other$$acellular senescence
000285023 650_7 $$2Other$$alate-life depression
000285023 650_7 $$2Other$$aneurodegeneration
000285023 650_7 $$2Other$$apsychotherapeutic treatment outcome
000285023 650_7 $$2NLM Chemicals$$aBiomarkers
000285023 650_2 $$2MeSH$$aHumans
000285023 650_2 $$2MeSH$$aBiomarkers: blood
000285023 650_2 $$2MeSH$$aAged
000285023 650_2 $$2MeSH$$aMale
000285023 650_2 $$2MeSH$$aFemale
000285023 650_2 $$2MeSH$$aMajor Depressive Disorder: therapy
000285023 650_2 $$2MeSH$$aMajor Depressive Disorder: blood
000285023 650_2 $$2MeSH$$aMiddle Aged
000285023 650_2 $$2MeSH$$aCognitive Behavioral Therapy
000285023 650_2 $$2MeSH$$aAged, 80 and over
000285023 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b1$$udzne
000285023 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b2
000285023 7001_ $$aBewernick, Bettina$$b3
000285023 7001_ $$aDomschke, Katharina$$b4
000285023 7001_ $$00000-0003-3927-6728$$aLuppa, Melanie$$b5
000285023 7001_ $$0P:(DE-2719)2000057$$aWagner, Michael$$b6
000285023 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b7$$udzne
000285023 7001_ $$0P:(DE-2719)9001189$$aFrölich, Lutz$$b8
000285023 7001_ $$00000-0003-4321-6090$$aRiedel-Heller, Steffi$$b9
000285023 7001_ $$aSchramm, Elisabeth$$b10
000285023 7001_ $$0P:(DE-2719)2812825$$aRamirez, Alfredo$$b11
000285023 7001_ $$00000-0002-9549-9208$$aDafsari, Forugh S$$b12
000285023 773__ $$0PERI:(DE-600)2005377-0$$a10.1192/j.eurpsy.2026.10153$$gVol. 69, no. 1, p. e18$$n1$$pe18$$tEuropean psychiatry$$v69$$x0924-9338$$y2026
000285023 8564_ $$uhttps://pub.dzne.de/record/285023/files/DZNE-2026-00148.pdf$$yRestricted
000285023 8564_ $$uhttps://pub.dzne.de/record/285023/files/DZNE-2026-00148.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285023 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000285023 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000285023 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000057$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285023 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811024$$aExternal Institute$$b7$$kExtern
000285023 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000285023 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285023 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2024-12-16$$wger
000285023 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-04T14:28:44Z
000285023 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-04T14:28:44Z
000285023 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-04T14:28:44Z
000285023 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR PSYCHIAT : 2022$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR PSYCHIAT : 2022$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-16
000285023 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-16
000285023 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x0
000285023 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x1
000285023 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x2
000285023 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x3
000285023 980__ $$ajournal
000285023 980__ $$aEDITORS
000285023 980__ $$aVDBINPRINT
000285023 980__ $$aI:(DE-2719)1011102
000285023 980__ $$aI:(DE-2719)1011303
000285023 980__ $$aI:(DE-2719)1011101
000285023 980__ $$aI:(DE-2719)1011201
000285023 980__ $$aUNRESTRICTED